Elderly lung cancer patients: what treatment strategies?

2007 ◽  
Vol 7 (10) ◽  
pp. 1331-1334 ◽  
Author(s):  
Cesare Gridelli
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Treatment Strategies ◽  
Lung Cancer Patients

Using Naïve Bayes Algorithm to Estimate the Response to Drug in Lung Cancer Patients

2019 ◽  
Vol 21 (10) ◽  
pp. 734-748 ◽  
Author(s):  
Baoling Guo ◽  
Qiuxiang Zheng
Keyword(s):  
Lung Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Drug Response ◽  
Treatment Options ◽  
Clinical Manifestations ◽  
Treatment Strategies ◽  
Cancer Resistance ◽  
Lung Cancer Patients ◽  
Bayes Algorithm

Aim and Objective: Lung cancer is a highly heterogeneous cancer, due to the significant differences in molecular levels, resulting in different clinical manifestations of lung cancer patients there is a big difference. Including disease characterization, drug response, the risk of recurrence, survival, etc. Method: Clinical patients with lung cancer do not have yet particularly effective treatment options, while patients with lung cancer resistance not only delayed the treatment cycle but also caused strong side effects. Therefore, if we can sum up the abnormalities of functional level from the molecular level, we can scientifically and effectively evaluate the patients' sensitivity to treatment and make the personalized treatment strategies to avoid the side effects caused by over-treatment and improve the prognosis. Result & Conclusion: According to the different sensitivities of lung cancer patients to drug response, this study screened out genes that were significantly associated with drug resistance. The bayes model was used to assess patient resistance.

scholarly journals Clinicopathological characteristics and treatment strategies for young lung cancer patients

2019 ◽  
Vol 7 (5) ◽  
pp. 100-100 ◽  
Author(s):  
Remi Yoneyama ◽  
Hisashi Saji ◽  
Yasufumi Kato ◽  
Yujin Kudo ◽  
Yoshihisa Shimada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Treatment Strategies ◽  
Clinicopathological Characteristics ◽  
Lung Cancer Patients

scholarly journals Alteration of Gut Microbiome in Lung Cancer Patients

2019 ◽  
Author(s):  
Li Ming ◽  
Yu Fang ◽  
Chen Xiaohui ◽  
Zhou Huan ◽  
Wei Xiaoqing ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Gut Microbiome ◽  
Treatment Strategies ◽  
Cancer Development ◽  
Healthy Individuals ◽  
Lung Cancer Patients ◽  
Microbial Dysbiosis ◽  
Treatment Naïve ◽  
Immunological Relationship

ABSTRACTLung cancer is the leading cause of cancer death. Better understanding of factors and pathways involved in lung cancer is needed to improve diagnose and treatment strategies. Recent studies have provided insights into the possible correlation between intestinal dysbiosis and cancer development. Although the immunological relationship between gut and lung had been suggested by many researches, however, to date, no study had investigated the characterization of gut microbiome in treatment naïve lung cancer patients, whether it is distinct from that of health individuals and contribute to the onset and development of lung cancer remain unclear. In this study, we investigated whether gut microbiome of lung cancer patients (LC, n=28) is altered compare with that of matched healthy individuals (HC, n=19) by high throughout sequencing of the V3-V4 regions of 16S rDNA in their fecal samples. We also identified microbiota signatures specific for different histological types of lung cancer, including SSC, ADC, and SCLC. The gut microbiome of lung cancer patients is characterized by decreased relative abundance of Prevotella, and increased bacteria groups such as Actinomyces, and Streptococcus, etc. We also detected a mild structural shift in gut microbiome between ADC and SCLC patients. Our results showed that the gut microbiome of lung cancer patients altered significantly compared with healthy individuals. However, the association between microbial dysbiosis and lung cancer is not clearly understood, future studies involving larger cohorts and metagenomics, or metabolomics, may elucidate the correlations between gut microbiota and lung cancer development.IMPORTANCEThis is the first report to show the alteration of gut microbiome in lung cancer patients. Our results showed that the gut microbiome of lung cancer patients altered significantly compared with healthy individuals.

scholarly journals Artificial Intelligence Applications to Improve the Treatment of Locally Advanced Non-Small Cell Lung Cancers

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2382
Author(s):  
Andrew Hope ◽  
Maikel Verduin ◽  
Thomas J Dilling ◽  
Ananya Choudhury ◽  
Rianne Fijten ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Locally Advanced ◽  
Unmet Need ◽  
Treatment Strategies ◽  
Clinical Decision Support Systems ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Locally advanced non-small cell lung cancer patients represent around one third of newly diagnosed lung cancer patients. There remains a large unmet need to find treatment strategies that can improve the survival of these patients while minimizing therapeutical side effects. Increasing the availability of patients’ data (imaging, electronic health records, patients’ reported outcomes, and genomics) will enable the application of AI algorithms to improve therapy selections. In this review, we discuss how artificial intelligence (AI) can be integral to improving clinical decision support systems. To realize this, a roadmap for AI must be defined. We define six milestones involving a broad spectrum of stakeholders, from physicians to patients, that we feel are necessary for an optimal transition of AI into the clinic.

scholarly journals Survival and Treatment of Lung Cancer in Taiwan between 2010 and 2016

2021 ◽  
Vol 10 (20) ◽  
pp. 4675
Author(s):  
Yen-Jung Chang ◽  
Jing-Yang Huang ◽  
Ching-Hsiung Lin ◽  
Bing-Yen Wang
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Randomized Clinical Trials ◽  
Treatment Strategies ◽  
Stage Iv ◽  
Clinical Staging ◽  
Lung Cancer Patients

Background: Lung cancer is the leading cause of cancer-related death, and its incidence is still growing in Taiwan. This study investigated the prognostic factors of overall survival between 2010 and 2016 in Taiwan. Methods: Data from 2010 to 2016 was collected from the Taiwan Cancer Registry (TCR). The characteristics and overall survival of 71,334 lung cancer patients were analyzed according to the tumor, node, metastasis (TNM) 7th staging system. Univariate and multivariate analysis were performed to identify the prognostic factors. Results: The five-year overall survival (n = 71,334) was 25.0%, and the median survival was 25.3 months. The five-year overall survival of patients receiving any kind of treatment (n = 65,436; 91.7%) and surgical resection (n = 20,131; 28.2%) was 27.09% and 69.93%, respectively. The clinical staging distribution was as follows: stage IA (9208, 12.9%), stage IB (4087, 5.7%), stage IIA (1702, 2.4%), stage IIB (1454, 2.0%), stage IIIA (5309, 7.4%), stage IIIB (6316, 8.9%), stage IV (41458, 58.1%). Age, sex, Charlson comorbidity index, cell type, clinical T, clinical N, clinical M, grading and treatment strategy are independent prognostic factors in the multivariate analysis. Conclusion: The outcome for lung cancer patients was still poor. The identification of prognostic factors could facilitate in choosing treatment strategies and designing further randomized clinical trials.

Molecular matching and treatment strategies for lung cancer at Dartmouth-Hitchcock Medical Center: A three year review of a molecular tumor board.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e20585-e20585
Author(s):  
Erica Bernhardt ◽  
Mary D. Chamberlin ◽  
Ivan P Gorlov ◽  
Francine B Blumental de Abreu ◽  
Katarzyna J Bloch ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Cancer Patients ◽  
Treatment Strategies ◽  
Genetic Alterations ◽  
Tumor Board ◽  
Barriers To Treatment ◽  
Lung Cancer Patients ◽  
Targeted Agent ◽  
Molecular Tumor Board

e20585 Background: Matching of actionable tumor mutations with targeted therapy has been shown to increase response rates and prolong survival in lung cancer patients. Drug development and trials targeting genetic alterations are expanding rapidly. We describe the role of a Molecular Tumor Board (MTB) in the design of molecularly informed treatment strategies in our lung cancer patient population. Methods: DNA from tumor specimens was sequenced to identify coding mutations using a 50-gene targeted next-generation sequencing panel (Ampliseq v2). Cases were evaluated by a multidisciplinary MTB that included medical oncologists, hematologists, molecular and anatomic pathologists, genetic counselors, and basic science researchers who suggested a course of treatment based on the patient’s molecular findings. Results: During a three-year period, 88 patients were presented to the MTB. Of these, 21 patients had lung cancer (23.9%). All patients lacked common (indicated for FDA approved drug) activating EGFR and ALK mutations. One patient was stage IIIb, all others were stage IV; 18 had previously received at least one prior line of therapy (range 0-5). Suggestions for treatment with a targeted therapy were made for 19 of 21 (90.5%) and four patients underwent treatment with a MTB-suggested targeted agent (21.1%); two as part of a clinical trial. One patient received targeted therapy for 27 months before his disease eventually progressed. Barriers to treatment with targeted therapy included: ineligibility for study (n = 2), lack of interest in study/distance to travel (n = 2), lack of disease progression (n = 2), death/hospice enrollment (n = 5), decision to treat with immunotherapy (n = 3), and unknown (n = 1). Conclusions: For the majority of lung cancer patients, the MTB was able to provide suggestions based on targetable genetic alterations. The largest barriers to treatment were death and hospice enrollment indicating that molecular testing and presentation to the MTB at earlier stages of disease may increase the number of patients who ultimately are eligible for treatment with a targeted agent.

scholarly journals Alteration of Gut Microbiome in Lung Cancer Patients- A Pilot Study 

2021 ◽  
Author(s):  
Ming Li ◽  
Fang Yu ◽  
Xiaohui Chen ◽  
Huan Zhou ◽  
Yinhui Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
16S Rdna ◽  
Gut Microbiome ◽  
Treatment Strategies ◽  
Cancer Development ◽  
Lung Cancer Patients ◽  
Microbial Dysbiosis ◽  
Rdna Sequencing ◽  
Treatment Naïve

Abstract Lung cancer is the leading cause of cancer death. Better understanding of factors and pathways involved in lung cancer is needed to improve diagnose and treatment strategies. Recent studies have provided insights into the possible correlation between intestinal dysbiosis and cancer development. Although the immunological relationship between gut and lung had been suggested by many researches, however, to date, no study had investigated the characterization of gut microbiome in treatment naïve lung cancer patients, whether it is distinct from that of health individuals and contribute to the onset and development of lung cancer remain unclear. In this study, we investigated whether gut microbiome of lung cancer patients (LC, n=28) is altered compare with that of matched healthy individuals (HC, n=19) by high throughout sequencing of the V3-V4 regions of 16S rDNA in their fecal samples. We also identified microbiota signatures specific for different histological types of lung cancer, including squamous cell carcinoma (SCC), adenocarcinoma (ADC) and small cell lung cancer (SCLC). 16S rDNA sequencing results showed that the gut microbiome of lung cancer patients is characterized by decreased relative abundance of Prevotella, and increased bacteria groups such as Actinomyces, and Streptococcus, etc. We also detected an obvious structural shift in gut microbiome between ADC and SCLC patients. However, given the limited number of study cases, the association between microbial dysbiosis and lung cancer is not clearly understood, future studies involving larger cohorts and metagenomics, or metabolomics, may elucidate the correlations between gut microbiota and lung cancer development.

Sign in / Sign up

Export Citation Format

Share Document